Drugs / BBO-10203
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06917079 | Mar 2025 → Aug 2027 expected | colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Recruiting | No outcome recorded |
| Phase 1 | NCT06625775 | Oct 2024 → Nov 2028 expected | HER2 positive breast carcinoma, colorectal cancer, hormone receptor-positive breast cancer, lung carcinoma | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Recruiting | No outcome recorded |
| Phase 1 | NCT06343402 | May 2024 → Apr 2031 expected | non-small cell lung carcinoma | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-04-21 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Results BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026 bbotx.com ↗
BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to signaling inhibition without inhibiting the kinase activity of PI3Kα and with no observed hyperglycemia |
| 2026-01-07 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Results BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs bbotx.com ↗
BBO-10203 demonstrated a potentially differentiated safety profile without any observed events of hyperglycemia and without any enrollment restrictions on baseline HbA1c and glucose levels; combination studies with standard-of-care (SOC) treatments in colorectal cancer (CRC) and breast cancer (BC) have been initiated; |
| 2025-10-30 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Results BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS) bbotx.com ↗
BBO-10203, a first-in-class breaker of the RAS:PI3Kα interaction, inhibits tumor growth alone and in combination with fulvestrant or ribociclib in breast cancer models without inducing hyperglycemia |
| 2025-10-23 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Results BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics bbotx.com ↗
Efficacy of the combination with BBOT’s RAS:PI3K ⍺ breaker, BBO-10203, is driven by a robust decrease in tumor cell proliferation and increase in apoptosis; combination benefit also observed with cetuximab and anti-PD-1 treatment |
| 2025-10-13 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Results BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics bbotx.com ↗
BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction inhibits tumor growth alone and in combination with KRAS inhibitors in KRAS mutant models without inducing hyperglycemia |
| 2025-06-12 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Results BBOT Announces Publication in Science Highlighting Preclinical Data that Supports the Potential for RAS:PI3Kα Breaker BBO-10203 to Provide Therapeutic Benefit across Multiple Tumor Types bbotx.com ↗
In preclinical models, BBO-10203 treatment led to significant tumor growth inhibition across multiple tumor types, and demonstrated enhanced efficacy when combined with other anti-tumor agents, without inducing hyperglycemia |
All press releases naming this drug 10 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBO-10203 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06917079 ↗ |
| Route | Oral | “BBO-10203 orally once daily” NCT06625775 ↗ |